Table 2 Characteristics and outcomes of patients with hematologic malignancies and COVID-19, according to COVID-19 clinical severity
Clinical severity of COVID-19 | ||||
|---|---|---|---|---|
Mild | Moderate | Severe | Critical | |
n (%) shown as proportions of patients within a row/category | ||||
Total (n = 692)* | 104 (15) | 159 (23) | 290 (42) | 139 (20) |
Age, years† | 63 (50–73) | 71 (58–79) | 74 (66–81) | 72 (63–81) |
18–49 (n = 72) | 26 (36) | 17 (24) | 20 (28) | 9 (13) |
50–59 (n = 93) | 23 (25) | 27 (29) | 28 (30) | 15 (16) |
60–69 (n = 130) | 19 (15) | 27 (21) | 51 (39) | 33 (25) |
70–79 (n = 225) | 23 (10) | 50 (22) | 110 (49) | 42 (19) |
> 80 (n = 171) | 13 (8) | 38 (22) | 80 (47) | 40 (23) |
Sex‡ | ||||
Female (n = 276) | 41 (15) | 73 (26) | 111 (40) | 51 (18) |
Male (n = 409) | 62 (15) | 83 (20) | 178 (44) | 86 (21) |
Comorbidities§, n | ||||
0 (n = 133) | 40 (30) | 32 (24) | 38 (29) | 23 (17) |
1 (n = 180) | 24 (13) | 49 (27) | 69 (38) | 38 (21) |
2 (n = 152) | 17 (11) | 33 (22) | 71 (47) | 31 (20) |
≥ 3 (n = 192) | 17 (9) | 34 (18) | 98 (51) | 43 (22) |
Hematologic malignancy | ||||
Lymphoid malignancies (n = 477)¶ | 75 (16) | 115 (24) | 196 (41) | 91 (19) |
Non-Hodgkin lymphoma (n = 187) | 33 (18) | 53 (28) | 71 (38) | 30 (16) |
Multiple myeloma (n = 136)ǁ | 23 (17) | 32 (23) | 61 (45) | 20 (15) |
Chronic lymphocytic leukemia (n = 109) | 9 (8) | 21 (19) | 47 (43) | 32 (29) |
Hodgkin lymphoma (n = 32)ǁ | 6 (19) | 7 (22) | 13 (41) | 6 (19) |
Acute lymphoid leukemia (n = 13) | 4 (31) | 2 (15) | 4 (31) | 3 (23) |
Myeloid malignancies (acute/subacute) (n = 139) | 17 (12) | 24 (17) | 62 (45) | 36 (26) |
Acute myeloid leukemia (n = 61) | 8 (13) | 8 (13) | 29 (48) | 16 (26) |
Myelodysplastic syndrome (n = 78) | 9 (12) | 16 (21) | 33 (42) | 20 (25) |
Myeloproliferative malignancies (n = 76)** | 12 (16) | 20 (26) | 32 (42) | 12 (16) |
Chronic myeloid leukemia (n = 16) | 4 (25) | 8 (50) | 3 (19) | 1 (6) |
Ph-negative myeloproliferative neoplasms (n = 60)** | 8 (13) | 12 (20) | 29 (48) | 11 (18) |
Hematopoietic stem cell transplantation†† | ||||
Autologous (n = 51) | 14 (27) | 15 (29) | 16 (31) | 6 (12) |
Allogeneic (n = 27) | 9 (33) | 4 (15) | 6 (22) | 8 (30) |
No (n = 585) | 79 (14) | 134 (23) | 256 (44) | 116 (20) |
Active antineoplastic treatment (n = 691)†,‡‡ | ||||
Conventional chemotherapy (n = 127) | 22 (17) | 25 (20) | 54 (43) | 26 (20) |
Low-intensity chemotherapy (n = 42) | 8 (19) | 10 (24) | 15 (36) | 9 (21) |
Molecular targeted therapies (n = 81)ǁ | 13 (16) | 20 (25) | 31 (38) | 17 (21) |
Monoclonal antibodies (n = 44) | 6 (14) | 10 (23) | 22 (50) | 6 (14) |
Immunomodulatory drugs (n = 44)ǁ | 5 (11) | 8 (18) | 26 (59) | 5 (11) |
Hypomethylating agents (n = 33) | 1 (3) | 10 (30) | 17 (52) | 5 (15) |
Supportive care (n = 12) | 0 | 4 (33) | 7 (58) | 1 (9) |
Not detailed (n = 22)¶ | 1 (5) | 6 (27) | 10 (45) | 5 (23) |
No active therapy (n = 286) | 47 (16) | 66 (23) | 108 (38) | 65 (23) |
Care setting | ||||
Ambulatory care (n = 89) | 57 (64) | 18 (20) | 13 (15) | 1 (1) |
Hospital care (n = 603)* | 47 (8) | 141 (23) | 277 (46) | 138 (23) |
Intensive care unit (n = 55)§§ | 2 (4) | 1 (2) | 10 (18) | 42 (76) |
Outcome | ||||
Survivors (n = 465)¶ | 101 (22) | 147 (32) | 170 (36) | 47 (10) |
Non-survivors (n = 227)** | 3 (1) | 12 (5) | 120 (53) | 92 (41) |